icon
موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية
icon الخميس 10 محرم 1448هـ
نسخة تجريبية
icon
روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
المواقع الالكترونية الحكومية تستخدم بروتوكول HTTPS للتشفير والأمان.

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
مسجل لدى هيئة الحكومة الرقمية برقم :
20250831619
اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 211 - 220 من 485
عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. King Abdullah Medical City, Holy Capital Ongoing • PANITUMUMAB• OXALIPLATIN• irinotecan• FLOUROURACIL 2 19-504 King Abdullah Medical City (Makkah)
Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer King Faisal Specialist Hospital and Research Centre Ongoing • TOCILIZUMAB (ACTEMRA)• DOCETAXEL (TAXOTERE)• CISPLATIN 2a 2181156 King Faisal Specialist Hospital and Research Center (Riyadh)
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension Biogen Ongoing Interferon beta-1a 3 105MS306 King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh)
"A multicenter, multinational, prospective, interventional,single-arm, Phase IV study evaluating the clinicalefficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin" SANOFI Ongoing TOUJEO 4 LPS15396 Sultan bin Abdulaziz Humanitarian city (Riyadh)
"A multi-centre prospective non-interventional studyinvestigating the clinical effectiveness of Ryzodeg® (InsulinDegludec/Insulin Aspart) in patients with type 2 diabetesmellitus in a real-world setting" Novo Nordisk Ongoing Ryzodeg Flex Touch 4 NN54014525 King Abdulaziz University Hospital (Jeddah), Ghassan Najeeb Pharaon hospital (Jeddah), Saudi German Hospital (Jeddah), Umm Al-Qura University (Makkah), Dallah Hospital (Riyadh), Riyadh Care Hospital (Riyadh), Specialized Medical Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
A prospective Randomized study of General Anesthesia versus Anesthetist Administered sedation for ERCP King Abdullah Medical City (Makkah) Ongoing FENTANYL/ CISATRACURIUM/ SEVOFLURANE 4 18-492 King Abdullah Medical City (Makkah)
CRAD001H2406- A long-term non-interventional observational study in Living Donor Liver Transplant Recipients (LDLTRs) with primary hepatocellular carcinoma (HCC) treated with Certican® / Zortress® (everolimus; EVR) plus reduced tacrolimus (rTAC) versus standard tacrolimus (sTAC) control Novartis Ongoing • everolimus • reduced tacrolimus 4 CRAD001H24 King Faisal Specialist Hospital and Research Center (Riyadh)
An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis Bristol-Myers Squibb Ongoing Abatacept 4 IM101240 King Abdulaziz Medical City NG (Riyadh)
A prospective, multicenter, observational study to evaluate patients’ quality oflife in routine clinical practice in patients with relapsing-remitting multiplesclerosis (RRMS) treated with LEMTRADA® Sanofi Ongoing alemtuzumab 4 OBS15590 Al-Noor Specialist Hospital (Makkah), King Khalid University Hospital (Riyadh), King Saud Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah)
A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with type 2 diabetes mellitus, treated with insulin glargine 300 U/mL (insulin glargine U300) before, during and after the period of Ramadan / ORION study Sanofi Ongoing Toujeo 4 OBS16040 King Abdulaziz University Hospital (Jeddah), Alzafer Hospital (Najran), University District Hospital (Jeddah), Saudi German Hospital (Jeddah)